Cartesian Therapeutics Overview
- Year Founded
-
2016

- Status
-
Public
- Employees
-
66

- Stock Symbol
-
RNAC

- Investments
-
1
- Share Price
-
$11.30
- (As of Tuesday Closing)
Cartesian Therapeutics General Information
Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Contact Information
Website
www.cartesiantherapeutics.comCorporate Office
- 704 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Corporate Office
- 704 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Cartesian Therapeutics Timeline
Cartesian Therapeutics Stock Performance
As of 08-Jul-2025, Cartesian Therapeutics’s stock price is $11.30. Its current market cap is $293M with 26M shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$11.30 | $10.77 | $8.46 - $26.50 | $293M | 26M | 80K | -$1.10 |
Cartesian Therapeutics Financials Summary
As of 31-Mar-2025, Cartesian Therapeutics has a trailing 12-month revenue of $34.9M.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 142,830 | 250,634 | 42,511 | 64,635 |
Revenue | 34,932 | 38,913 | 26,004 | 110,777 |
EBITDA | (35,899) | (83,323) | (239,998) | 39,088 |
Net Income | (38,310) | (77,424) | (219,710) | 35,379 |
Total Assets | 409,130 | 435,023 | 305,050 | 165,886 |
Total Debt | 14,066 | 13,984 | 10,955 | 37,925 |
Cartesian Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Cartesian Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Cartesian Therapeutics Comparisons
Industry
Financing
Details
Cartesian Therapeutics Competitors (10)
One of Cartesian Therapeutics’s 10 competitors is IM Therapeutics, a Venture Capital-Backed company based in Woburn, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
IM Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
Intensity Therapeutics | Formerly PE-Backed | Shelton, CT | ||||
Vitruvian Biomedical | Angel-Backed | Addison, TX | ||||
Collaborative Medicinal Development | Venture Capital-Backed | Mill Valley, CA | ||||
Sirnaomics | Formerly VC-backed | Gaithersburg, MD |
Cartesian Therapeutics Patents
Cartesian Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023321906-A1 | Compositions and methods related to immunoglobulin proteases and fusions thereof | Pending | 11-Aug-2022 | ||
EP-4568750-A1 | Compositions and methods related to immunoglobulin proteases and fusions thereof | Pending | 11-Aug-2022 | ||
US-20240148841-A1 | Compositions and methods related to immunoglobulin proteases and fusions thereof | Pending | 11-Aug-2022 | ||
US-20230381277-A1 | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance | Pending | 08-Apr-2022 | ||
US-20230372535-A1 | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents | Pending | 25-Mar-2022 | A61K47/6931 |
Cartesian Therapeutics Signals
Cartesian Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Cartesian Therapeutics Acquisitions (1)
Cartesian Therapeutics’s most recent deal was a Merger/Acquisition with Selecta Biosciences. The deal was made on 13-Nov-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Selecta Biosciences | 13-Nov-2023 | Merger/Acquisition | Drug Discovery |
Cartesian Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
36.37 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile

Pharmaceuticals
Industry
of 847
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Cartesian Therapeutics Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Selecta Biosciences | Watertown, MA | 2008 |
Cartesian Therapeutics FAQs
-
When was Cartesian Therapeutics founded?
Cartesian Therapeutics was founded in 2016.
-
Where is Cartesian Therapeutics headquartered?
Cartesian Therapeutics is headquartered in Gaithersburg, MD.
-
What is the size of Cartesian Therapeutics?
Cartesian Therapeutics has 66 total employees.
-
What industry is Cartesian Therapeutics in?
Cartesian Therapeutics’s primary industry is Biotechnology.
-
Is Cartesian Therapeutics a private or public company?
Cartesian Therapeutics is a Public company.
-
What is Cartesian Therapeutics’s stock symbol?
The ticker symbol for Cartesian Therapeutics is RNAC.
-
What is the current stock price of Cartesian Therapeutics?
As of 08-Jul-2025 the stock price of Cartesian Therapeutics is $11.30.
-
What is the current market cap of Cartesian Therapeutics?
The current market capitalization of Cartesian Therapeutics is $293M.
-
What is Cartesian Therapeutics’s current revenue?
The trailing twelve month revenue for Cartesian Therapeutics is $34.9M.
-
Who are Cartesian Therapeutics’s competitors?
IM Therapeutics, Intensity Therapeutics, Vitruvian Biomedical, Collaborative Medicinal Development, and Sirnaomics are some of the 10 competitors of Cartesian Therapeutics.
-
What is Cartesian Therapeutics’s annual earnings per share (EPS)?
Cartesian Therapeutics’s EPS for 12 months was -$1.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »